A Phase 1 Study of LY4170156 in People With Solid Tumors

Full Title

A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody- Drug Conjugate Targeting Folate Receptor alpha-Expressing Tumor Cells, in Participants with Selected Advanced Solid Tumors

Purpose

Researchers want to find the best dose of LY4170156 to treat people with solid tumors. The people in this study have solid tumors that keep growing even after treatment. Their tumors also make a protein called FRA, which plays a role in cancer growth. The tumors treated in this study include:

• Breast cancer
• Ovarian cancer
• Cervical cancer
• Endometrial cancer
• Colorectal cancer
• Non-small cell lung cancer
• Pancreatic cancer

LY4170156 is a type of drug called an antibody-drug conjugate (ADC). ADCs are made up of an antibody linked to a drug. The antibody binds to a cancer cell, and the drug enters the cell and kill it.

LY4170156 targets cells that make FRA. By destroying these cells, LY4170156 may help slow or stop the growth of your cancer. It is given intravenously (by vein).

Contact

For more information and to see if you can join this study, please call 646-888-4226.